Major Sjögren’s Syndrome (pSS) has been characterised as a hypersensitivity response sort II systemic autoimmune persistent illness inflicting exocrine gland dysfunction primarily affecting girls close to the menopausal age. pSS sufferers exhibit dryness of the principle mucosal surfaces and are extremely susceptible to lymphoma improvement. This paper presents a primary biomedical ontology for pSS based mostly on a reference mannequin which was decided by pSS scientific specialists.
The following ontology constitutes the elemental foundation for mapping pSS-related ontologies from worldwide cohorts to a typical ontology. The ontology mapping (i.e., schematic interlinking) process is, in reality, a preliminary step to harmonize heterogeneous medical knowledge obtained from numerous cohorts.
Freedom and the psychoanalytic ontology of quantum physics.
Jung’s paper ‘Synchronicity – an acausal connecting precept’, defining the phenomenon as a ‘significant’ coincidence relying on archetypal activation, was revealed in 1952, along with a conceptually associated piece by physicist and Nobel Laureate Wolfgang Pauli entitled, ‘The affect of archetypal concepts on the scientific theories of Kepler’. Slavoj Žižek, in The Indivisible The rest: On Schelling and Associated Issues, means that, in distinction to any notion of a ‘pre-modern Jungian concord’, the principle lesson of quantum physics was that not solely was the psychoanalytic, empty topic of the signifier constitutively out-of-joint with respect to the world, however that the Actual in itself was already incomplete, out-of-joint, ‘not-all’.
But whereas Žižek ceaselessly tries to separate Jung from his personal ontology, this paper reveals that his ontology will not be as totally different as he suggests. In step with our earlier publications on Jung and Zizek, a better investigation reveals an underlying congruence of each of their approaches. On this paper we present that this affinity lies within the rejection by each Jung and Žižek of the ideology of reductive materialism, a rejection that demonstrably attracts on quantum physics in related methods. Whereas Jung posits an inherently significant universe, Žižek makes an attempt to salvage the liberty of human subjectivity by opposing his Lacanian ‘dialectical materialism’ to reductive materialism.
Ontology-based systematic illustration and evaluation of conventional Chinese language medication towards rheumatism.
Rheumatism represents any illness situation marked with irritation and ache within the joints, muscle tissues, or connective tissues. Many conventional Chinese language medication have been used for a very long time to deal with rheumatism. Nonetheless, a complete data supply for these medication continues to be lacking, and their anti-rheumatism mechanisms stay unclear. An ontology for anti-rheumatism conventional Chinese language medication would strongly assist the illustration, evaluation, and understanding of those medication.
On this research, we first systematically collected reported details about 26 conventional Chinese language decoction items medication, together with their chemical components and adversarial occasions (AEs). By largely reusing phrases from current ontologies (e.g., TCMDPO for conventional Chinese language medicines, NCBITaxon for taxonomy, ChEBI for chemical parts, and OAE for adversarial occasions) and making semantic axioms linking totally different entities, we developed the Ontology of Chinese language Medication for Rheumatism (OCMR) that features over 3000 class phrases.
|
Recombinant Humanp21 Recombinant Protein |
|
ProSci |
|
Recombinant phosphopantetheine adenylyltransferase (PPAT) (Recombinant) |
|
Abbexa |
|
Glyco Recombinant Protein A33 Recombinant Protein |
|
ProSci |
|
Glyco Recombinant Protein A33 Recombinant Protein |
|
ProSci |
|
STAG3L1 Recombinant Protein (Human) (Recombinant Tag) |
|
ABM |
Our OCMR evaluation discovered that these 26 conventional Chinese language decoction items are made out of anatomic entities (e.g., root and stem) from three Bilateria animals and 23 Mesangiospermae vegetation. Anti-inflammatory and antineoplastic roles are essential for anti-rheumatism medication. Utilizing the entire of 555 distinctive ChEBI chemical entities recognized from these medication, our ChEBI-based classification evaluation recognized 18 anti-inflammatory, 33 antineoplastic chemical substances, and 9 chemical substances (together with three diterpenoids and three triterpenoids) having each anti-inflammatory and antineoplastic roles.
Moreover, our research detected 22 diterpenoids and 23 triterpenoids, together with 16 pentacyclic triterpenoids which might be seemingly bioactive towards rheumatism. Six medication have been discovered to be related to 184 distinctive AEs, together with three AEs (i.e., dizziness, nausea and vomiting, and anorexia) every related to 5 medication. A number of chemical entities are labeled as neurotoxins (e.g., diethyl phthalate) and allergens (e.g., eugenol), which can clarify the formation of some TCD AEs. The OCMR might be effectively queried for helpful data utilizing SPARQL scripts.
The OCMR ontology was developed to systematically symbolize 26 conventional anti-rheumatism Chinese language medication and their associated data. The OCMR evaluation recognized attainable anti-rheumatism and AE mechanisms of those medication. Our novel ontology-based strategy can be utilized to systematic illustration and evaluation of different conventional Chinese language medication.
|
Recombinant Humanp21 Recombinant Protein |
|
92-035 |
|
Recombinant phosphopantetheine adenylyltransferase (PPAT) (Recombinant) |
|
20-abx072018 |
|
Glyco Recombinant Protein A33 Recombinant Protein |
|
96-361 |
|
Glyco Recombinant Protein A33 Recombinant Protein |
|
96-364 |
|
STAG3L1 Recombinant Protein (Human) (Recombinant Tag) |
|
RP030283 |
Quick and Correct Metadata Authoring Utilizing Ontology-Primarily based Suggestions.
In biomedicine, high-quality metadata are essential for locating experimental datasets, for understanding how experiments have been carried out, and for reproducing these experiments. Regardless of the current deal with metadata, the standard of metadata accessible in public repositories continues to be extraordinarily poor. A key issue is that the standard metadata acquisition course of is time-consuming and error susceptible, with weak or nonexistent assist for linking metadata to ontologies.
There’s a urgent want for strategies and instruments to hurry up the metadata acquisition course of and to extend the standard of metadata which might be entered. On this paper, we describe a technique and set of related instruments that we developed to deal with this problem.
 Antibody) Reticulocalbin 1 (RCN1) Antibody |
|
20-abx126465 |
Abbexa |
-
EUR 493.20
-
EUR 710.40
-
EUR 218.40
-
EUR 376.80
|
- 100 ul
- 200 ul
- 20 ul
- 50 ul
|
|
|
 RCN1 Polyclonal Conjugated Antibody |
|
C27480 |
SAB |
100ul |
EUR 476.4 |
 RCN1 Rabbit pAb |
|
A10572-100ul |
Abclonal |
100 ul |
EUR 369.6 |
RCN1 Rabbit pAb |
|
A10572-200ul |
Abclonal |
200 ul |
EUR 550.8 |
RCN1 Rabbit pAb |
|
A10572-20ul |
Abclonal |
20 ul |
EUR 219.6 |
RCN1 Rabbit pAb |
|
A10572-50ul |
Abclonal |
50 ul |
EUR 267.6 |
 RCN1 cloning plasmid |
|
CSB-CL618980HU-10ug |
Cusabio |
10ug |
EUR 279.6 |
|
|
|
Description: A cloning plasmid for the RCN1 gene. |
 Protein) Reticulocalbin 1 (RCN1) Protein |
|
20-abx262856 |
Abbexa |
-
EUR 393.60
-
EUR 7676.40
-
EUR 276.00
|
|
|
|
) RCN1 protein (His tag) |
|
80R-1434 |
Fitzgerald |
50 ug |
EUR 366 |
|
Description: Purified recombinant Human RCN1 protein |
 Human RCN1 shRNA Plasmid |
|
20-abx954030 |
Abbexa |
|
|
|
|
 Mouse RCN1 shRNA Plasmid |
|
20-abx972413 |
Abbexa |
|
|
|
|
) Human Reticulocalbin-1 (RCN1) |
|
1-CSB-YP618980HU |
Cusabio |
-
EUR 516.00
-
EUR 280.80
-
EUR 1809.60
-
EUR 770.40
-
EUR 1210.80
-
EUR 349.20
|
- 100ug
- 10ug
- 1MG
- 200ug
- 500ug
- 50ug
|
|
|
|
Description: Recombinant Human Reticulocalbin-1(RCN1),partial expressed in Yeast |
) RCN1 Recombinant Protein (Human) |
|
RP026077 |
ABM |
100 ug |
Ask for price |
) RCN1 Recombinant Protein (Rat) |
|
RP223949 |
ABM |
100 ug |
Ask for price |
) Anti-RCN1 (1F8-E4) |
|
YF-MA15139 |
Abfrontier |
100 ug |
EUR 435.6 |
|
Description: Mouse monoclonal to RCN1 |
) Anti-RCN1 (4D9-G3) |
|
YF-MA15140 |
Abfrontier |
100 ug |
EUR 435.6 |
|
Description: Mouse monoclonal to RCN1 |
) RCN1 Recombinant Protein (Mouse) |
|
RP167399 |
ABM |
100 ug |
Ask for price |
 (pORF)) Rcn1 ORF Vector (Rat) (pORF) |
|
ORF074651 |
ABM |
1.0 ug DNA |
EUR 607.2 |
 (pORF)) Rcn1 ORF Vector (Mouse) (pORF) |
|
ORF055801 |
ABM |
1.0 ug DNA |
EUR 607.2 |
 (OKEI00324)) RCN1 ELISA Kit (Human) (OKEI00324) |
|
OKEI00324 |
Aviva Systems Biology |
96 Wells |
EUR 920.4 |
|
Description: Description of target: May regulate calcium-dependent activities in the endoplasmic reticulum lumen or post-ER compartment. ;Species reactivity: Human;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.375 ng/mL |
 (pORF)) RCN1 ORF Vector (Human) (pORF) |
|
ORF008693 |
ABM |
1.0 ug DNA |
EUR 114 |
ELISA Kit) Human Reticulocalbin 1 (RCN1)ELISA Kit |
|
201-12-2939 |
SunredBio |
96 tests |
EUR 528 |
|
|
|
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids. |
 ELISA Kit) Human Reticulocalbin 1 (RCN1) ELISA Kit |
|
abx253097-96tests |
Abbexa |
96 tests |
EUR 848.4 |
|
|
 ELISA Kit) Human RCN1(Reticulocalbin 1) ELISA Kit |
|
EH3705 |
FN Test |
96T |
EUR 628.92 |
|
|
|
Description: Method of detection: Double Antibody, Sandwich ELISA;Reacts with: Homo sapiens;Sensitivity: 0.375 ng/ml |
) RCN1 sgRNA CRISPR Lentivector set (Human) |
|
K1803801 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
) Rcn1 sgRNA CRISPR Lentivector set (Mouse) |
|
K4781201 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
) Rcn1 sgRNA CRISPR Lentivector set (Rat) |
|
K6523601 |
ABM |
3 x 1.0 ug |
EUR 406.8 |
 RCN1 Reticulocalbin 1 Human Recombinant Protein |
|
PROTQ15293 |
BosterBio |
Regular: 10ug |
EUR 380.4 |
|
Description: RCN1 Recombinant Human produced in E.Coli is a single, non-glycosylated polypeptide chain containing 341 amino acids (30-331 a.a.) and having a molecular mass of 40.4kDa (real molecular weight on SDS-PAGE will be shift up). The RCN1 is fused to 39 amino acid His-Tag at N-terminus and purified by proprietary chromatographic techniques. |
 (Target 1)) RCN1 sgRNA CRISPR Lentivector (Human) (Target 1) |
|
K1803802 |
ABM |
1.0 ug DNA |
EUR 184.8 |
 (Target 2)) RCN1 sgRNA CRISPR Lentivector (Human) (Target 2) |
|
K1803803 |
ABM |
1.0 ug DNA |
EUR 184.8 |
 (Target 3)) RCN1 sgRNA CRISPR Lentivector (Human) (Target 3) |
|
K1803804 |
ABM |
1.0 ug DNA |
EUR 184.8 |
 (Target 1)) Rcn1 sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|
K4781202 |
ABM |
1.0 ug DNA |
EUR 184.8 |
 (Target 2)) Rcn1 sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|
K4781203 |
ABM |
1.0 ug DNA |
EUR 184.8 |
 (Target 3)) Rcn1 sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|
K4781204 |
ABM |
1.0 ug DNA |
EUR 184.8 |
 (Target 1)) Rcn1 sgRNA CRISPR Lentivector (Rat) (Target 1) |
|
K6523602 |
ABM |
1.0 ug DNA |
EUR 184.8 |
 (Target 2)) Rcn1 sgRNA CRISPR Lentivector (Rat) (Target 2) |
|
K6523603 |
ABM |
1.0 ug DNA |
EUR 184.8 |
 (Target 3)) Rcn1 sgRNA CRISPR Lentivector (Rat) (Target 3) |
|
K6523604 |
ABM |
1.0 ug DNA |
EUR 184.8 |
) ELISA kit for Human RCN1 (Reticulocalbin 1) |
|
E-EL-H5569 |
Elabscience Biotech |
1 plate of 96 wells |
EUR 640.8 |
|
|
|
Description: A sandwich ELISA kit for quantitative measurement of Human RCN1 (Reticulocalbin 1) in samples from Serum, Plasma, Cell supernatant |
 (pPB-C-His)) RCN1 Protein Vector (Human) (pPB-C-His) |
|
PV034769 |
ABM |
500 ng |
EUR 394.8 |
 (pPB-N-His)) RCN1 Protein Vector (Human) (pPB-N-His) |
|
PV034770 |
ABM |
500 ng |
EUR 394.8 |
 (pPM-C-HA)) RCN1 Protein Vector (Human) (pPM-C-HA) |
|
PV034771 |
ABM |
500 ng |
EUR 394.8 |
 (pPM-C-His)) RCN1 Protein Vector (Human) (pPM-C-His) |
|
PV034772 |
ABM |
500 ng |
EUR 394.8 |
 (pPB-C-His)) RCN1 Protein Vector (Mouse) (pPB-C-His) |
|
PV223202 |
ABM |
500 ng |
EUR 723.6 |
 (pPB-N-His)) RCN1 Protein Vector (Mouse) (pPB-N-His) |
|
PV223203 |
ABM |
500 ng |
EUR 723.6 |
 (pPM-C-HA)) RCN1 Protein Vector (Mouse) (pPM-C-HA) |
|
PV223204 |
ABM |
500 ng |
EUR 723.6 |
 (pPM-C-His)) RCN1 Protein Vector (Mouse) (pPM-C-His) |
|
PV223205 |
ABM |
500 ng |
EUR 723.6 |
 (pPB-C-His)) RCN1 Protein Vector (Rat) (pPB-C-His) |
|
PV298602 |
ABM |
500 ng |
EUR 723.6 |
 (pPB-N-His)) RCN1 Protein Vector (Rat) (pPB-N-His) |
|
PV298603 |
ABM |
500 ng |
EUR 723.6 |
 (pPM-C-HA)) RCN1 Protein Vector (Rat) (pPM-C-HA) |
|
PV298604 |
ABM |
500 ng |
EUR 723.6 |
 (pPM-C-His)) RCN1 Protein Vector (Rat) (pPM-C-His) |
|
PV298605 |
ABM |
500 ng |
EUR 723.6 |
 Rcn1 3'UTR GFP Stable Cell Line |
|
TU267430 |
ABM |
1.0 ml |
Ask for price |
 RCN1 3'UTR Luciferase Stable Cell Line |
|
TU019702 |
ABM |
1.0 ml |
EUR 1672.8 |
 RCN1 3'UTR GFP Stable Cell Line |
|
TU069702 |
ABM |
1.0 ml |
EUR 1672.8 |
 Rcn1 3'UTR Luciferase Stable Cell Line |
|
TU217430 |
ABM |
1.0 ml |
Ask for price |
Rcn1 3'UTR GFP Stable Cell Line |
|
TU167670 |
ABM |
1.0 ml |
Ask for price |
Rcn1 3'UTR Luciferase Stable Cell Line |
|
TU117670 |
ABM |
1.0 ml |
Ask for price |
 (UbC) (pLenti-GIII-UbC)) RCN1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|
LV792577 |
ABM |
1.0 ug DNA |
EUR 379.2 |
 (EF1a) (pLenti-GIII-EF1a)) RCN1 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|
LV792578 |
ABM |
1.0 ug DNA |
EUR 379.2 |
 (CMV) (pLenti-GIII-CMV)) RCN1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|
LV647263 |
ABM |
1.0 ug DNA |
EUR 616.8 |
 (UbC) (pLenti-GIII-UbC)) RCN1 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|
LV647267 |
ABM |
1.0 ug DNA |
EUR 616.8 |
 (EF1a) (pLenti-GIII-EF1a)) RCN1 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|
LV647268 |
ABM |
1.0 ug DNA |
EUR 616.8 |
 [His]) Recombinant Saccharomyces Cerevisiae RCN1 Protein (aa 1-211) [His] |
|
VAng-Wyb5435-1mg |
Creative Biolabs |
1 mg |
EUR 4864.8 |
|
Description: Saccharomyces Cerevisiae (strain ATCC 204508 / S288c) Rcn1p protein, recombinant protein. |
) RCN1 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|
K1803805 |
ABM |
3 x 1.0 ug |
EUR 451.2 |
) Rcn1 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
|
K4781205 |
ABM |
3 x 1.0 ug |
EUR 451.2 |
) Rcn1 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat) |
|
K6523605 |
ABM |
3 x 1.0 ug |
EUR 451.2 |
 (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)) RCN1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|
LV792576 |
ABM |
1.0 ug DNA |
EUR 448.8 |
 (CMV) (pLenti-GIII-CMV-C-term-HA)) RCN1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|
LV647264 |
ABM |
1.0 ug DNA |
EUR 616.8 |
 (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)) RCN1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|
LV647265 |
ABM |
1.0 ug DNA |
EUR 686.4 |
 (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)) RCN1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|
LV647266 |
ABM |
1.0 ug DNA |
EUR 686.4 |
 (Target 1)) RCN1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|
K1803806 |
ABM |
1.0 ug DNA |
EUR 200.4 |
 (Target 2)) RCN1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|
K1803807 |
ABM |
1.0 ug DNA |
EUR 200.4 |
 (Target 3)) RCN1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|
K1803808 |
ABM |
1.0 ug DNA |
EUR 200.4 |
 (Target 1)) Rcn1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1) |
|
K4781206 |
ABM |
1.0 ug DNA |
EUR 200.4 |
 (Target 2)) Rcn1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2) |
|
K4781207 |
ABM |
1.0 ug DNA |
EUR 200.4 |
 (Target 3)) Rcn1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3) |
|
K4781208 |
ABM |
1.0 ug DNA |
EUR 200.4 |
 (Target 1)) Rcn1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1) |
|
K6523606 |
ABM |
1.0 ug DNA |
EUR 200.4 |
 (Target 2)) Rcn1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2) |
|
K6523607 |
ABM |
1.0 ug DNA |
EUR 200.4 |
 (Target 3)) Rcn1 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3) |
|
K6523608 |
ABM |
1.0 ug DNA |
EUR 200.4 |
 ASAP1 antibody Antibody |
|
DF8746 |
Affbiotech |
200ul |
EUR 420 |
 anti- Antibody^Polyclonal antibody control antibody |
|
LSMab09882 |
Lifescience Market |
100 ug |
EUR 525.6 |
 Antibody) Anti-Glycolipid Antibody (AGA) Antibody |
|
20-abx004855 |
Abbexa |
-
EUR 493.20
-
EUR 710.40
-
EUR 218.40
-
EUR 376.80
|
- 100 ul
- 200 ul
- 20 ul
- 50 ul
|
|
|
 Antibody) Ly1 Antibody Reactive (LYAR) Antibody |
|
20-abx008109 |
Abbexa |
-
EUR 360.00
-
EUR 526.80
-
EUR 226.80
|
|
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|
20-abx123734 |
Abbexa |
|
|
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|
20-abx014333 |
Abbexa |
-
EUR 376.80
-
EUR 117.60
-
EUR 477.60
-
EUR 594.00
|
- 100 ug
- 10 ug
- 200 ug
- 300 µg
|
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|
abx033330-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|
abx033330-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
|
Anti-Glycolipid Antibody (AGA) Antibody |
|
abx036399-100ug |
Abbexa |
100 ug |
EUR 469.2 |
|
|
 Antibody) Anti-Glycoprotein Antibody (GP) Antibody |
|
20-abx319900 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
|
20-abx319901 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
|
20-abx319905 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
|
Anti-Glycoprotein Antibody (GP) Antibody |
|
20-abx319913 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
|
Anti-Glycolipid Antibody (AGA) Antibody |
|
abx230204-100ug |
Abbexa |
100 ug |
EUR 577.2 |
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|
20-abx324434 |
Abbexa |
|
|
|
|
Ly1 Antibody Reactive (LYAR) Antibody |
|
20-abx311665 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
|
A core element of this strategy is a price advice framework that makes use of evaluation of beforehand entered metadata and ontology-based metadata specs to assist customers quickly and precisely enter their metadata. We carried out an preliminary analysis of this strategy utilizing metadata from a public metadata repository.
